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OBJECTIVES—Recently, an association was found between
diabetic nephropathy and the D18S880 microsatellite, located in
the carnosinase gene (CNDP1) on chromosome 18q. Alleles of
this microsatellite encode for a variable number of leucine
residues (from four to seven) in the leader peptide of the
carnosinase precursor. The frequency of subjects homozygous
for the ﬁve leucines was higher in control subjects than in case
subjects in studies focusing on type 2 diabetic patients. To test
whether this ﬁnding can be extended to type 1 diabetic patients,
we carried out a comprehensive study on association between
diabetic nephropathy and the D18S880 microsatellite and 21
additional SNPs that tagged the genomic region containing
CNDP1 and CNDP2.
RESEARCH DESIGN AND METHODS—Overall, 1,269 Cauca-
sian patients with type 1 diabetes were included in the study,
including 613 patients with normoalbuminuria and a long dura-
tion of diabetes, 445 patients with persistent proteinuria, and 211
patients with end-stage renal disease (ESRD). All patients were
genotyped for selected polymorphisms, the associations with
diabetic nephropathy were tested by a 
2 test, and odds ratios
were calculated.
RESULTS—We did not ﬁnd any signiﬁcant association between
diabetic nephropathy and any examined genetic markers. The
negative ﬁndings of the case-control study were supported
further by negative ﬁndings obtained from the 6-year follow-up
study of 445 patients with persistent proteinuria, during which
135 patients developed ESRD.
CONCLUSIONS—Our large, comprehensive study did not ﬁnd
an association between the D18S880 microsatellite or any other
polymorphisms in the CNDP2–CNDP1 genomic region and sus-
ceptibility for diabetic nephropathy in type 1 diabetes. Diabetes
57:2547–2551, 2008
D
iabetic nephropathy is the most severe compli-
cation resulting from type 1 diabetes. Approxi-
mately 30 to 40% of type 1 diabetic patients
develop this complication, which leads to end-
stage renal disease (ESRD) and increases the risk of
cardiovascular morbidity and mortality (1–3). Epidemio-
logic and family studies have demonstrated that in addi-
tion to levels of glycemic control, genetic factors play an
important role in the development of diabetic nephropathy
(4–6). Many groups have been searching for genes that
make individuals susceptible to diabetic nephropathy us-
ing linkage studies or candidate gene approaches (7).
Recently, a family study conducted in 19 Turkish extended
families exhibiting type 2 diabetes showed evidence for
linkage between microalbuminuria and proteinuria and the
genomic region on chromosome 18q22.3–q23 (8). Following
these ﬁndings, Janssen et al. (9) found an association be-
tween diabetic nephropathy and the common sequence vari-
ant in the carnosinase 1 gene (CNDP1) located in that region.
The case-control study, however, consisted of only 135 case
and 107 control subjects (both groups consisted of type 1 and
type 2 diabetic individuals)selected from among patients in
four different countries. In that study, association was found
between microsatellite D18S880, a trinucleotide repeat in
exon 2 of CNDP1, and diabetic nephropathy. Because this
polymorphism lies in the 5 coding part of the transcript,
the number of trinucleotide repeats is directly related to the
number of leucine residues in the leader peptide of the
carnosinase precursor: ﬁve, six, or seven leucines. The fre-
quency of subjects homozygous for the ﬁve leucines was
higher in control subjects compared with case subjects. The
odds ratio (OR) of diabetic nephropathy for carriers of four,
six, or seven leucines, in comparison with those homozygous
for the ﬁve leucines, was 2.6 (95% CI 1.4–4.8). Interestingly,
functional studies carried out by the same group provided
some support for a biological explanation of the observed
association (9–11).
Recently, Freedman et al. (12) published data from a
case-control study in which the authors selected case
(patients with type 2 diabetes and ESRD) and control
(individuals with type 2 diabetes but without diabetic
nephropathy) subjects from among Caucasians in North
Carolina. The cases were ascertained through dialysis
centers, and the control subjects were recruited as volun-
teers for the Diabetes Heart Study. This study supported
Janssen et al.’s (5) ﬁndings that subjects with diabetes but
without diabetic nephropathy were more frequently ho-
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DIABETES, VOL. 57, SEPTEMBER 2008 2547mozygous for the ﬁve-leucine repeat genotype than those
who had ESRD. Although both studies concluded that the
ﬁve-leucine repeat was protecting against diabetic ne-
phropathy, the effect of duration of diabetes on frequency
of this genotype in control and case subjects was not
examined in either study (13).
In this report, we attempted to extend the ﬁndings of
Janssen et al. and Freedman et al. (9,12) to patients with
type 1 diabetes. We examined the association between the
number of leucine repeats in CNDP1 and other tagging
single nucleotide polymorphisms (SNPs) in the CNDP2-
CNDP1 genomic region and the risk of various stages of
diabetic nephropathy in a population of Caucasian pa-
tients with type 1 diabetes living in the eastern part of
Massachusetts and attending a large diabetes center. Large
case-control as well as follow-up study designs were used.
RESEARCH DESIGN AND METHODS
Patients for this investigation were selected from the Joslin Study on Genetics
of Diabetic Nephropathy in type 1 Diabetes. The detailed description of the
Joslin clinic population and the method of selection of patients for the study
can be found in the online appendix (available at http://dx.doi.org/10.2337/
db07-1303). The Committee on Human Subjects of the Joslin Diabetes Center
approved the protocol and informed consent procedures for the study.
Diagnosis of type 1 diabetes and diabetic nephropathy. Patients were
considered type 1 diabetic if hyperglycemia was diagnosed before age 40
years, its control required insulin treatment within 1 year of diagnosis, and
such treatment could not be interrupted thereafter. Only patients aged 18–59
years at examination were eligible for enrollment into these studies. The
diabetic nephropathy status of each patient was determined on the basis of
medical records and measurements of the urinary albumin-to-creatinine ratio.
Methods for measuring the albumin-to-creatinine ratio and classiﬁcation
criteria have previously been described (14). At the time of enrollment,
patients were classiﬁed into the following study groups (detailed description
of the criteria can be found in the online appendix): 1) Control subjects were
considered to have normoalbuminuria if they had diabetes duration of 15
years and had persistent normoalbuminuria; 2) Case subjects were considered
to have persistent microalbuminuria if they had diabetes duration 3 years
and had persistent microalbuminuria; 3) Case subjects were considered to
have persistent proteinuria if they had diabetes 7 years and had persistent
proteinuria; and 4) Case subjects were considered to have ESRD if they had
begun dialysis or received a renal transplant as a result of diabetic nephrop-
athy. Patients with proteinuria at the enrollment were followed until 2005 to
determine who progressed to ESRD.
DNA was extracted using a standard phenol-chloroform protocol. For the
current study, we used only patients classiﬁed as control subjects (n  613)
or case subjects with advanced diabetic nephropathy (445 with proteinuria
and 211 with ESRD). Patients with microalbuminuria were not examined in
the current investigation. In total, 1,269 patients from the Joslin Study on
Genetics of Diabetic Nephropathy in type 1 Diabetes were used in this
investigation.
D18S880 microsatellite was genotyped using previously described primers
(9) and standard PCR protocols. The PCR products were separated using the
ABI 377 Sequencer (Perkin Elmer, Foster City, CA). All samples were
successfully genotyped for microsatellite markers. All selected SNPs were
genotyped using Sequenom MassArray Platform (Broad Institute Center for
Genotyping and Analysis, Cambridge, MA). The maximum SNP-speciﬁc miss-
ing data rate was 4.7%.
Selection of SNPs. We identiﬁed haploblocks in the CNDP2 gene locus with
the D 90% conﬁdence bounds method of Gabriel et al. (15) using Haploview
software (16). We selected tagging SNPs (htSNPs) needed to tag frequent
haplotypes in a block (frequency 0.05) using the method of Stram et al. (17).
The minimum set of htSNPs within each block was selected to ensure an Rh
2
of at least 0.80 for all haplotypes observed at a frequency of at least 5%. In this
set of htSNPs, the minimum Rh
2 was always 0.80. For the CNDP2 locus, we
selected 12 htSNPs, which cover two haploblocks denoted as A and B and one
inter-block denoted as C. Because of less clear haploblock structure in the
A B
Controls versus Proteinurics (P – value)
SNP 1234567 89 10 11 12 13 14 15 16 17 18 19 20 21
* 0.88 0.38 0.23 0.55 0.21 0.51 0.91 0.75 0.65 0.61 0.29 0.66 0.93 0.82 0.98 0.59 0.53 0.74 0.42 0.43 0.28
** 0.74 0.43 0.09 0.50 0.83 0.40 0.76 0.85 0.98 0.64 0.43 0.42 0.87 0.80 0.88 0.31 0.26 0.69 0.19 0.20 0.11
Controls versus ESRD (P – value)
SNP 123 4 5 6 7 8 91 0 1 1 1 2 13 14 15 16 17 18 19 20 21
* 0.90 0.66 0.41 0.60 0.83 0.07 0.50 0.50 0.10 0.36 0.33 0.27 0.04 0.03 0.06 0.79 0.02 0.86 0.82 0.54 0.58
** 0.87 0.59 0.21 0.42 0.57 0.04 0.26 0.30 0.04 0.15 0.34 0.18 0.01 0.01 0.02 0.68 0.17 0.63 0.69 0.97 0.87
* 2 degree of freedom
** additive mode of inheritance
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FIG. 1. Approximate genomic location and P values for selected single SNP comparisons for the CNDP1 and CNDP2 genomic regions assuming
additive mode of inheritance. Nominal P values for 
2 tests with 2 d.f. are also provided. Haploblocks are shown schematically as gray rectangles.
SNPs 1–12 are considered tagging SNPs for particular haplo- and interblocks. *2 d.f.; **additive mode of inheritance.
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minor allele frequency 5%. This included two SNPs used previously by
Janssen et al. (9). In total, we genotyped one microsatellite located in exon 2
and 9 SNPs in the CNDP1 locus. These SNPs were grouped into three loosely
deﬁned haploblocks (Fig. 1).
Power calculations. To calculate the sample size required to replicate the
association of leucine repeats with diabetic nephropathy, we assumed a
protective allele frequency of 59% and a genotype relative risk (RR) of 2.56
(estimated based on OR) for individuals who are not ﬁve-leucine homozy-
gotes(9). We assumed a diabetic nephropathy prevalence of 30%. Under these
assumptions, we estimated that 613 control and 656 case subjects would
provide 99% power to conﬁrm the ﬁndings reported by Janssen et al. (9). On
the other hand, if we used 211 ESRD case and 613 control subjects we would
have had 80% power to detect an OR of 1.61, assuming the recessive model.
OR 1.51 for the dominant model, or OR 1.28 for the additive model at the P 
0.05 level of statistical signiﬁcance. Power calculations were performed with
the program CaTS of Skol et al. (18) (available at http://www.sph.umich.edu/
csg/abecasis/CaTS/). In our follow-up study, we were able to detect a genotype
RR of 1.5 with a power of at least 80% at the P  0.05 level of statistical
signiﬁcance. To calculate power in the follow-up branch of our study, we used
the PS program of Dupont and Plummer (19) (available at http://www.
mc.vanderbilt.edu/prevmed/ps/index.htm).
Statistical analysis. The data from the study were analyzed using SAS
(version 8.02; SAS Institute, Cary, NC). Deviations from Hardy-Weinberg
equilibrium were evaluated with a 
2 goodness-of-ﬁt test. For single-marker
analysis, we used Snpgwa, version 1.0, software under assumptions of additive
models. We tested the association between the genotype polymorphisms and
diabetic nephropathy using a 
2 test and calculated ORs. The Haplo.stat
package was used to infer and compare haplotype distribution with the
skip.haplo option set to 0.05 (20).
In the follow-up study, we calculated life tables to compute incidence rates.
The observation ended at the year of the development of ESRD, death, loss to
follow-up, or 2005. Additionally, a Cox proportional hazards model controlling
for several covariates was constructed to examine the effect of genotypes on
risk of ESRD .
RESULTS
Characteristics of the study groups are shown in Table 1.
They reﬂect the study design. Age at diagnosis of type 1
diabetes was similar in all groups, all patients had long
duration of diabetes, all were treated with insulin (data not
shown), and all had similar A1C and BMI. However,
patients with proteinuria and ESRD had longer duration of
diabetes (and therefore were older) and higher blood
pressure than control subjects.
Figure 1 shows the genomic region that contains CNDP2
and CNDP1. Both genes are located on the long arm of
chromosome 18 (18q22.3) in a tail-to-head orientation.
CNDP2 spans 24.8 kb and has 12 exons. CNDP1 is 13 kb
telomeric from CNDP2, which spans 50.6 kb and also has
12 exons. The linkage disequilibrium (LD) structure of
CNDP2 allows us to distinguish two haploblocks (A and B)
followed by an interval (C) without haploblock structure.
CNDP1 is characterized by a less clear haploblock struc-
ture, and the selected SNPs were grouped into three
intervals: D, E, and F. Overall, in the CNDP2-CNDP1
genomic region, we selected and genotyped 21 SNPs and
the D18S880 microsatellite. All SNPs were in Harvey-
Weinberg equilibrium.
The results of single SNP analysis are shown in the
bottom part of Fig. 1 and in an online appendix. None of
the examined SNPs appeared to be signiﬁcantly differently
distributed between control and case subjects with pro-
teinuria or ESRD except for SNPs located in the interval D,
which contains a proximal and distal promoter of CNDP1.
Genotype frequencies of these three SNPs were different
at P  0.05 between control and case subjects with ESRD.
However, the differences became insigniﬁcant after Bon-
ferroni adjustment. Haplotype analysis of these three
SNPs did not yield a more signiﬁcant difference between
control and case subjects with ESRD (data not shown).
The results for the D18S880 microsatellite were ana-
lyzed separately. Five alleles corresponding to repeats of
four, ﬁve, six, seven, and eight leucines were found. The
ﬁrst and last alleles were very rare (1%). The frequency
of the allele encoding the ﬁve leucines, the protective
allele from the Janssen et al. report, was very similar in all
three study groups: 57.8% in patients with normoalbumin-
uria and long-duration type 1 diabetes (control subjects)
and 54.8 and 59.2% for patients with proteinuria and ESRD,
respectively. The frequency of other alleles was also very
similar. Overall, the distribution of the alleles did not differ
among the three study groups (P  0.2) (Table 2A in the
online appendix).
TABLE 2
Distribution of genotypes for D18S880 microsatelitte according
to study groups
D18S880
genotypes
Control subjects
with
normoalbuminuria
Case subjects
with
proteinuria
Case subjects
with ESRD
n 613 445 211
5_5 33.0 29.4 32.2
5_6 43.6 45.2 47.9
5_7 6.0 5.4 6.2
6_6 12.6 15.5 11.8
X_X 4.9 4.5 1.9
Genotype frequency data are percent. Genotypes with frequencies
5% were combined to X_X. Control subjects with diabetes duration
25 and 25 years had similar distribution of the D185880 genotype.
Total 
2  7.50; 8 d.f.; P  0.48.
TABLE 1
Selected clinical characteristics of patients in the study group according to nephropathy status at time of enrollment into the study
Normoalbuminuria Proteinuria ESRD
n 613 445 211
Men (%) 46.8 53.5 56.9
Age at diabetes diagnosis (years) 13.2  7.4 12.0  8.0 11.6  6.3
Duration of diabetes (years) 21.8  9.7 24.9  8.5 31.0  7.3
Age at examination (years) 35.0  9.2 38.4  8.8 42.6  6.6
A1C (%) 7.8  1.2 9.0  1.7 8.1  2.0
Systolic blood pressure (mmHg) 118  13 134  18 134  20
Diastolic blood pressure (mmHg) 71  87 9  10 76  11
BMI (kg/m
2) 25.0  3.5 26.1  5.4 24.5  4.9
Median ACR (mg/g) 10.7  52 1,402  1,337 —
Data are means  SD unless otherwise indicated. ACR, albumin-to-creatinine ratio.
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groups are presented in Table 2. In this table, the geno-
types less frequent than 5% were combined into one group
referred to as the X_X genotype. The frequency of subjects
homozygous for ﬁve leucines was very similar in the three
study groups. The frequencies of other genotypes were
also similar (P  0.5). Combined analysis of the D18S880,
in which control subjects were compared with case sub-
jects (patients with proteinuria or ESRD), also failed to
replicate results published by Janssen et al. The OR in our
study was 1.13 (95% CI 0.89–1.43).
To further study the associations between ESRD and the
three SNPs located in interval D with the D18S880 geno-
types, we conducted a follow-up study. In this study, 445
patients with proteinuria were followed for an average of
5.6 years (range 3–16). During the follow-up, 135 patients
with proteinuria developed ESRD. Table 3 shows the
results of the follow-up study. Incidence rates of ESRD
during follow-up were not different according to geno-
types of the three examined SNPs or the D18S880 micro-
satellite. The Cox proportional hazards model was also
constructed to examine the effect of genotypes on risk of
ESRD, controlling for covariates such as sex, age at
diagnosis of diabetes, duration of diabetes, and treatment
with ACE inhibitors or lack thereof. This analysis also did
not reveal any difference in risk of developing ESRD
according to the examined genotypes (Table 3).
DISCUSSION
Recently, an association was found between diabetic
nephropathy and the D18S880 microsatellite in the car-
nosinase gene (CNDP1) (9). Alleles of this microsatellite
encode for a variable number of leucine residues (from
four to seven) in the leader peptide of the carnosinase
precursor. Homozygotes for the ﬁve leucines were found
less frequently among patients with diabetic nephropathy
than among patients without it (9). To test whether this
ﬁnding, which has signiﬁcant biological implications, can
be extended to patients with type 1 diabetes, we carried
out a large comprehensive examination of association
between various stages of diabetic nephropathy and the
D18S880 microsatellite, as well as 21 SNPs that tagged the
genomic region containing CNDP2 and CNDP1. Unfortu-
nately, we did not ﬁnd any signiﬁcant association between
diabetic nephropathy and any of the examined genetic
markers. Noteworthy, three SNPs in the promoter region
of CNDP1 (rs12954438, rs8903332, and rs11151964) could
be considered associated with ESRD, assuming the addi-
tive inheritance model at the nominal P  0.05 signiﬁcance
level. However, those SNPs have never been studied
before. Moreover, based on our data, those SNPs are not in
LD with any of the D18S880 alleles. Therefore, we consid-
ered our examination of the SNPs in the promoter region
of the CNDP1 gene as exploratory study and employed
stringent Bonferroni correction. The negative ﬁndings of
the case-control study were supported further by negative
ﬁndings obtained in the 6-year follow-up study of 445
patients with persistent proteinuria, during which 135
patients developed ESRD. In conclusion, our large com-
prehensive study did not support the role of D18S880
microsatellite or any other polymorphisms of CNDP2 and
CNDP1 in the development of diabetic nephropathy in
type 1 diabetes. Following, we discuss our results in
comparison with ﬁndings from the other studies.
Table 4 shows the frequency of CNDP1 ﬁve leucine/ﬁve
leucine genotype in control and case subjects in each of
the three studies. Due to the small number of individuals
with type 1 diabetes in the study by Janssen et al. (9), we
TABLE 3
Incidence of ESRD during the follow-up according to genotypes of the selected four markers
Polymorphism Genotype n ESRD PYs IR/100 PYs HR (95% CI) P
rs12954438* A/A A/G 101 30 516 5.8 1.0 (Ref.)
G/G 335 103 1,885 5.5 1.02 (0.67–1.53) 0.94
rs890332* G/G A/G 101 30 515 5.8 1.0 (Ref.)
A/A 334 103 1,871 5.5 1.02 (0.67–1.53) 0.94
rs11151964* A/A A/G 109 32 590 5.4 1.0 (Ref.)
G/G 331 102 1,840 5.5 1.04 (0.69–1.56) 0.86
D18S880 55 131 34 746 4.6 1.0 (Ref.)
5X 226 82 1,196 6.9 1.34 (0.90–2.02) 0.15
XX 88 19 512 3.7 0.79 (0.44–1.39) 0.41
For the polymorphism D18S880, alleles 4, 6, and 7 were combined to X. HRs presented are for each of the selected polymorphisms according
to genotypes. n  patients with proteinuria at the entry of the study. *Due to small number of risk homozygotes, the data for the carriers
of the risk allele have been combined. ESRD, new cases of ESRD; IR/100 PYs, incidence rate per 100 patient-years; PY, patient-years.
TABLE 4
Comparison of frequency of CNDP1 ﬁve leucine/ﬁve leucine repeat genotype in case (patients with diabetic nephropathy) and control
(individuals with diabetes) subjects in the three studies
Study n
Percent of 5–5
in control subjects
Percent of 5–5
in case subjects
OR*
(5–5 as reference)
Janssen et al. (9): type 1 and type 2 diabetes** 242 43 27 2.0 (1.17–3.42)
Freedman et al. (12): type 2 diabetes 600 39 29 1.5 (1.07–2.13)
Wanic et al. (current study): type 1 diabetes 1,269 33 30 1.1 (0.89–1.43)
*95% CIs are provided in parenthesis, and ORs calculated for the protective effect. **Including 57 patients with type 1 and 185 with type 2
diabetes. 5–5, ﬁve leucine/ﬁve leucine repeat genotype.
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diabetic and type 2 diabetic patients. Interestingly, the
frequency of the ﬁve/ﬁve homozygotes in case subjects is
very similar in the three studies (differences were not
statistically signiﬁcant: 
2  0.5; P  0.8). The frequency of
the ﬁve/ﬁve homozygotes seems to be different among the
control subjects, being most frequent in the Janssen et al.
study, intermediate in the Freedman et al. study, and
lowest in the current study (
2  5.6; P  0.06). The ﬁrst
study was the smallest and used patients from four differ-
ent countries, including one Arabic country. The study by
Freedman et al. (12) selected case and control subjects
from among European-Americans residing in North Caro-
lina but did so through completely different mechanisms.
The case subjects were found through dialysis centers. The
control subjects were recruited as volunteers for the Diabe-
tes Heart Study. Only the current study drew case and
control subjects from the same clinic population, and it
included more case and control subjects than the two other
studies combined.
At present, there is no clear explanation for the discrep-
ant ﬁndings summarized in Table 4. One possibility is that
they result from improper selection of control subjects in
some of the studies. However, because the differences in
the previous studies were observed in patients with type 2
diabetes, one cannot exclude the possibility that the ﬁve
leucine/ﬁve leucine genotype of the D18S880 microsatel-
lite plays a role in protection against diabetic nephropathy
in patients with type 2 diabetes but not type 1 diabetes.
Therefore, the discrepant ﬁndings may simply indicate
differences in genetic susceptibility to diabetic nephropa-
thy in type 1 and type 2 diabetes (21).
Additionally, we examined the possibility that the
D18S880 microsatellite alleles are not causally related to
diabetic nephropathy but are in LD with other DNA
sequence differences that are causal. To test this possibil-
ity, we examined 21 SNPs that encompass most of the
genetic variation in the CNDP2-CNDP1 genomic region.
Neither single-SNP nor haplotype analysis showed any
signiﬁcant association with proteinuria or ESRD. How-
ever, these negative ﬁndings should be qualiﬁed because
the haploblock structure, particularly for CNDP1 locus, is
poorly deﬁned in the current HapMap data. Furthermore,
we had only limited information to estimate LD between
the D18S880 microsatellite and other SNPs in the CNDP2-
CNDP1 genomic region.
Some other qualiﬁcations of our ﬁndings should be
discussed. First, although our study is large, it is too small
to detect signiﬁcant ORs below 1.2. To demonstrate such a
small effect, one would need several thousand case and
control subjects, as was demonstrated recently in studies
on type 2 diabetes (22,23). The cross-sectional part of our
study might have been underpowered to detect ORs
reported by Freedman et al. (12). However, this deﬁciency
was overcome by implementing the follow-up study,
which had sufﬁcient power to detect a genotype RR of 1.5.
Second, it is well known that patients with ESRD have
very high mortality, and some of the associations may not
be related to risk of the development of ESRD but may
instead determine survival of such patients. In our study,
we excluded such a possibility by examining the risk of
development of ESRD according to speciﬁc genotypes in
the prospective study. Finally, spurious associations or
lack thereof can result from poor quality of genotyping. In
our study, we used manual genotyping, which can be
susceptible to errors, for D18S880 microsatellite. How-
ever, we had only a few errors when we repeated geno-
typing in 10% of the study population. On the other hand,
tagging SNPs were genotyped on the Sequenom platform
with almost perfect genotyping.
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